A new molecular imaging radiotracer can precisely diagnose a variety of cancers, providing a roadmap to identify patients who may benefit from targeted radionuclide therapies. In the largest medical study of its kind, researchers ...
Nov 17, 2022
0
49
Often undetected until it has progressed to an advanced stage, pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer. The K-Ras mutant pancreatic cancer is one of the most common types. At present, there are no effective ...
Jun 6, 2022
0
1
Researchers at the Abramson Cancer Center at the University of Pennsylvania have found a way to identify lung cancer at the cellular level in real time during a biopsy, offering promise in the ability to detect the disease ...
May 18, 2022
0
45
Nearly 13% of women born in the U.S. today will develop breast cancer at some point during their lives. Treatment for early-stage disease often includes breast-conserving surgery, where the tumor and some surrounding healthy ...
May 17, 2022
0
14
Effective combination therapies are urgently needed to treat triple-negative breast cancer (TNBC), which is insensitive to the existing treatment regimens. However, the synergistic potency of traditional small-molecule combinations ...
Apr 12, 2022
0
3
A trio of researchers working at the Albert Einstein College of Medicine has found that giving biologic agents to metastatic colorectal cancer patients improved survivability for black and white patients nearly equally. In ...
In treating cancer, personalized medicine means recognizing that the same disease can behave differently from one patient to another, and precision medicine means that diagnosis and treatment should involve understanding ...
Oct 13, 2021
0
12
The ruthenium-based anticancer agent BOLD-100 just received an Orphan Drug Designation in the treatment of gastric (stomach) cancer from the U.S. Food and Drug Administration. The small molecule therapeutic originally developed ...
Jul 21, 2021
0
1
A Ludwig Cancer Research study has found that inducing random chromosome instability (CIN) events in mice for as little as one week is enough to trigger harmful chromosomal patterns in cells that spur the formation of tumors.
Jul 16, 2021
0
34
The anti-programmed death receptor 1 (PD-1) monotherapy Jemperli (dostarlimab) received approval for treatment of mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer that has progressed after treatment ...
Apr 26, 2021
0
3
